Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Zevra Denmark A/S has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 2 distinct art units, indicating broad examiner coverage across a smaller set of art-unit assignments.
CORNET, JEAN P is the busiest examiner, with 1 pending matter. Counsel should coordinate recurring art-unit issues while preserving examiner-specific response strategies for the active matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 41.7% | +47.4% |
| DAHLIN, HEATHER RAQUEL | 1 | 41.9% | +46.0% |
| SCHMITT, MICHAEL J | 1 | 56.9% | +19.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037461 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | DAHLIN, HEATHER RAQUEL | 37d overdue |
| 18267591 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | CORNET, JEAN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037461 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | DAHLIN, HEATHER RAQUEL | 37d overdue |
| 17560549 | USE OF ARIMOCLOMOL IN THE TREATMENT OF NIEMANN PICK DISEASE | SCHMITT, MICHAEL J | 14d |
| 18267591 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18267591 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | CORNET, JEAN P | 1628 | §102§103 | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18037461 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | DAHLIN, HEATHER RAQUEL | 1629 | §103§112 | Non-Final OA | 37d overdue | Pending | May 17, 2023 |
| 17560549 | USE OF ARIMOCLOMOL IN THE TREATMENT OF NIEMANN PICK DISEASE | SCHMITT, MICHAEL J | 1629 | §103DP | Non-Final OA | 14d | Pending | Dec 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZevra Denmark A/S has 3 pending office actions as of November 2026, spread across 2 art units and 3 examiners.
Jean P Cornet has the most, with 1 of Zevra Denmark A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.